Stock Track | Hims & Hers Health Soars 11.14% Intraday on FDA Peptide Regulation Easing and Novo Nordisk Partnership

Stock Track

Apr 17

Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 11.14% on Thursday, extending gains from the previous session. The telehealth company's stock has been rallying strongly following major positive developments.

The sharp rise was primarily driven by an announcement from U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who stated that the government would move to loosen regulations for 12 peptides. The Food and Drug Administration plans to convene an expert panel in July to discuss whether compounding pharmacies can produce these popular peptide substances, which could expand regulated access to peptide-based treatments.

Additionally, Hims & Hers has entered into a partnership with pharmaceutical giant Novo Nordisk to sell weight-loss drugs on its platform. This regulatory pivot and commercial partnership are seen as significant growth catalysts for the company, which had previously indicated plans to enter the peptide business and acquired a California-based manufacturing facility last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1165129367"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165129367\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165129367?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 02:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165129367","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 11.14% Intraday on FDA Peptide Regulation Easing and Novo Nordisk Partnership","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 11.14% on Thursday, extending gains from the previous session. The telehealth company's stock has been rallying strongly following major positive developments.</p><p>The sharp rise was primarily driven by an announcement from U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who stated that the government would move to loosen regulations for 12 peptides. The Food and Drug Administration plans to convene an expert panel in July to discuss whether compounding pharmacies can produce these popular peptide substances, which could expand regulated access to peptide-based treatments.</p><p>Additionally, Hims & Hers has entered into a partnership with pharmaceutical giant Novo Nordisk to sell weight-loss drugs on its platform. This regulatory pivot and commercial partnership are seen as significant growth catalysts for the company, which had previously indicated plans to enter the peptide business and acquired a California-based manufacturing facility last year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 11.14% Intraday on FDA Peptide Regulation Easing and Novo Nordisk Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 11.14% Intraday on FDA Peptide Regulation Easing and Novo Nordisk Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-17 02:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 11.14% on Thursday, extending gains from the previous session. The telehealth company's stock has been rallying strongly following major positive developments.</p><p>The sharp rise was primarily driven by an announcement from U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who stated that the government would move to loosen regulations for 12 peptides. The Food and Drug Administration plans to convene an expert panel in July to discuss whether compounding pharmacies can produce these popular peptide substances, which could expand regulated access to peptide-based treatments.</p><p>Additionally, Hims & Hers has entered into a partnership with pharmaceutical giant Novo Nordisk to sell weight-loss drugs on its platform. This regulatory pivot and commercial partnership are seen as significant growth catalysts for the company, which had previously indicated plans to enter the peptide business and acquired a California-based manufacturing facility last year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1165129367","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165129367","pubTimestamp":1776363912,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 11.14% on Thursday, extending gains from the previous session. The telehealth company's stock has been rallying strongly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘中大涨11.14%受FDA多肽监管放松和诺和诺德合作影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 11.14% on Thursday, extending gains from the previous session. The telehealth company's stock has been rallying strongly following major positive developments.The sharp rise was primarily driven by an announcement from U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who stated that the government would move to loosen regulations for 12 peptides. The Food and Drug Administration plans to convene an expert panel in July to discuss whether compounding pharmacies can produce these popular peptide substances, which could expand regulated access to peptide-based treatments.Additionally, Hims & Hers has entered into a partnership with pharmaceutical giant Novo Nordisk to sell weight-loss drugs on its platform. This regulatory pivot and commercial partnership are seen as significant growth catalysts for the company, which had previously indicated plans to enter the peptide business and acquired a California-based manufacturing facility last year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}